- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT02406352
Multispectral Digital Colposcope With Probe for Detection of Cervical Intraepithelial Neoplasia (MDCwProbe)
Development and Application of a Multispectral Digital Colposcope and Probe Algorithm for Detection of Cervical Intraepithelial Neoplasia
Studie Overzicht
Toestand
Conditie
Interventie / Behandeling
Gedetailleerde beschrijving
The multispectral digital colposcope (MDC) is a specialized lightsource and imaging device mounted on a custom-made colposcope that acquires a sequence of fluorescence images. This version of the MDC incorporates an upgraded light source, and updates the firmware and the user interface. This results in shorter acquisition times and improved image and spectrum quality control. The MDC also consists of a point probe that is used to take detailed light measurements (call spectroscopy) from smaller regions of the cervix. The goal of the study is to see whether the MDC can perform better than standard methods in detecting cancerous or pre-cancerous abnormalities of the cervix.
Study subjects will be swabbed for detection and typing of the Human Papilloma Virus (HPV). After vinegar is applied on the cervix as per usual colposcopy practice, the MDC will then be used to take a sequence of images of the cervix. Next 2-4 readings will be taken from the cervix using the point probe.
This data will be used to train, test and validate an algorithm specific to the MDC. The ability of the algorithm to detect cervical intraepithelial neoplasia will be compared to standard clinical care (colposcopy).
The MDC images and pathology results will be compared to the spectroscopy data from the MDC probe. The investigators will determine if spectroscopy has equal sensitivity to colposcopy for detecting high grade lesions.
Studietype
Inschrijving (Verwacht)
Fase
- Niet toepasbaar
Contacten en locaties
Studie Locaties
-
-
New York
-
Brooklyn, New York, Verenigde Staten, 11212
- Werving
- Brookdale University Hospital and Medical Center
-
Contact:
- Leonid Fradkin, PhD
- Telefoonnummer: 718-240-8225
- E-mail: lfradkin@bhmcny.org
-
Contact:
- Thelma Carrillo, MPH
- Telefoonnummer: 718-240-5978
- E-mail: tcarrill@bhmcny.org
-
Hoofdonderzoeker:
- Michele Follen, MD, PhD
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
- Women who are at least 18 years old
- Are not pregnant (negative urine test) or breastfeeding
- Referred for colposcopy or LEEP treatment
- Can provide written informed consent
Exclusion Criteria:
- Women who do not meet the inclusion criteria
- Women who have had a hysterectomy
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Diagnostisch
- Toewijzing: NVT
- Interventioneel model: Opdracht voor een enkele groep
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Experimenteel: Routine colposcopy and MDC with probe
The intervention which consists of obtaining cervical images with the MDC and spectroscopic data with the probe will be applied to all participants who agreed to participate in the study during their visit for a colposcopy exam or treatment with a LEEP procedure.
A control biopsy will also be obtained from patients who agree to provide it.
The control biopsy is a biopsy of cervical tissue that does not appear to have atypical changes when observed through a standard of care colposcope.
|
Cervical images will be obtained with the Multispectral Digital Colposcope. Spectroscopic data will be obtained with the probe from eligible patients who provided consent to participate in the study. The standard of care for research participants will not change. |
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Detection of precancerous cervical lesions or cervical cancer
Tijdsspanne: At point of care for colposcopy or treatment with LEEP (5 minutes).
|
Eligible patients who are referred to the colposcopy clinic for a diagnosis following an abnormal Pap smear will be asked to participate in the study. All participating women will receive their standard of care colposcopy as usual. In addition to their routine care, the MDC with probe will also be used to collect images of the cervix and spectroscopic measurements with the probe. All measurements will be compared with the biopsies obtained. The MDC with probe will not be used to determine from where the biopsies need to be obtained. One or two additional biopsies will be obtained from tissue that appears to be unaffected. These will be the control biopsies. Patients may refuse to provide the additional biopsies which are not part of the standard of care. Patients scheduled for a treatment with the Loop Electrosurgical Excision Procedure (LEEP) will be asked for consent to obtain one or two biopsies prior to the LEEP procedure, but after anesthesia has been applied. |
At point of care for colposcopy or treatment with LEEP (5 minutes).
|
Medewerkers en onderzoekers
Onderzoekers
- Hoofdonderzoeker: Michele Follen, MD, PhD, Brookdale University Hospital and Medical Center
Studie record data
Bestudeer belangrijke data
Studie start
Primaire voltooiing (Verwacht)
Studie voltooiing (Verwacht)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Schatting)
Updates van studierecords
Laatste update geplaatst (Schatting)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- 14-35
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .
Klinische onderzoeken op Carcinoom in situ van de baarmoederhals
-
Mithra PharmaceuticalsVoltooidCervix Intra-epitheliale neoplasie | Baarmoeder Cervicale NeoplasieBelgië
-
CG Oncology, Inc.BeëindigdCarcinoom in Situ | Overgangscelcarcinoom | Blaaskanker | Carcinoma in situ gelijktijdig met papillaire tumorenVerenigde Staten
-
Barretos Cancer HospitalVoltooidCervicale intra-epitheliale neoplasie | Cervix neoplasmaBrazilië
-
Mithra PharmaceuticalsVoltooidBaarmoeder Cervicale Neoplasmata | Cervix Intra-epitheliale neoplasieBelgië
-
Michael A. O'DonnellWervingBlaaskanker | Urotheelcarcinoom | BCG-niet-reagerende blaaskanker | Niet-spierinvasieve blaaskanker (NMIBC) | Carcinoma in Situ (CIS) | Hooggradige papillair blaastumoren | Ta Stadium Blaaskanker | T1 Stadium Blaaskanker | BCG-refractaire blaaskanker | Hoogrisico NMIBC | Micropapillaire Variant Urotheelcarcinoom...Verenigde Staten
-
UNC Lineberger Comprehensive Cancer CenterEunice Kennedy Shriver National Institute of Child Health and Human Development...VoltooidBaarmoederhalskanker | Cervix intra-epitheliale neoplasie graad 3 | Baarmoederhals; Intra-epitheliale neoplasie, graad I | Baarmoederhals; Intra-epitheliale neoplasie, graad IIKenia
-
Antiva BiosciencesVoltooidBaarmoederhalskanker | Cervicale intra-epitheliale neoplasie | CIN | Humaan papillomavirus | Cervicale dysplasie | HSIL van Cervix | Cervicaal neoplasma | HSIL | Hoogwaardige squameuze intra-epitheliale laesies | Hoogwaardige cervicale intra-epitheliale neoplasieVerenigde Staten, Australië
-
Antiva BiosciencesVoltooidBaarmoederhalskanker | Humaan papillomavirus | HSIL, hoogwaardige squameuze intra-epitheliale laesies | Cervicale dysplasie | HSIL van Cervix | Hoogwaardige cervicale intra-epitheliale neoplasie | Hiv-negatief | CIN - Cervicale intra-epitheliale neoplasie | Cervicaal neoplasmaZuid-Afrika